How were Anchiano Therapeutics' earnings last quarter?

Anchiano Therapeutics Ltd. (NASDAQ:ANCN) posted its quarterly earnings results on Monday, August, 5th. The company reported ($0.05) earnings per share (EPS) for the quarter, beating the consensus estimate of ($0.17) by $0.12.

What other stocks do shareholders of Anchiano Therapeutics own?

Based on aggregate information from My MarketBeat watchlists, some companies that other Anchiano Therapeutics investors own include AbbVie (ABBV) , Allena Pharmaceuticals (ALNA) , Aileron Therapeutics (ALRN) , Abeona Therapeutics (ABEO) , Achieve Life Sciences (ACHV) , Acorda Therapeutics (ACOR) , Acasti Pharma (ACST) , Aduro Biotech (ADRO) and AnaptysBio (ANAB) .

When did Anchiano Therapeutics IPO?

Anchiano Therapeutics (ANCN) raised $35 million in an initial public offering (IPO) on Tuesday, February 12th 2019. The company issued 2,400,000 shares at $14.55 per share. Oppenheimer acted as the underwriter for the IPO and Ladenburg Thalmann was co-manager.

NASDAQ:ANCN

Anchiano Therapeutics (ANCN) Stock Price, News & Analysis

→ The #1 Crypto for 2024 (From InvestorPlace) (Ad)

Free ANCN Stock Alerts

Notice: This company has been marked as potentially delisted and may not be actively trading.

Compare

Today's Range: $0.66
▼
$0.74
50-Day Range: $2.82
▼
$59.00
52-Week Range: $0.51
▼
$10.55

Volume: 15,392 shs
Average Volume: 3.15 million shs
Market Capitalization: $5.05 million

P/E Ratio: 4.53
Dividend Yield: N/A
Price Target: N/A

Stock Analysis Competitors Social Media

Get Anchiano Therapeutics alerts:

Ad Paradigm Press

Forget Bitcoin. Crypto Millionaire Predicts 8,788% Gains For THIS

You might have seen that Bitcoin was one of the best performing assets of 2023. It gained 164%. But a crypto millionaire who has been tracking the space for more than a decade has ABANDONED Bitcoin. He found something better.

Click here to find out that this 8,788% cryptocurrency is.

About Anchiano Therapeutics Stock (NASDAQ:ANCN)

Anchiano Therapeutics Ltd., a preclinical biotechnology company, discovers, develops, and commercializes small molecule anti-cancer therapies. It primarily develops Pan-RAS Program that identifies novel indene-based small molecules that exhibit potent and selective inhibition of activated RAS signaling regardless of isoform or mutation; and PDE10/Ã-catenin program, which identifies small molecules that selectively and potently inhibit PDE10 and suppress Wnt/APC/Ã-catenin signaling in preclinical models. Anchiano Therapeutics Ltd. has collaboration and license agreement with ADT Pharmaceuticals, LLC to research and develop programs related to the pan-RAS and PDE10/Ã-catenin programs. The company was formerly known as BioCancell Ltd. and changed its name Anchiano Therapeutics Ltd. in July 2018. Anchiano Therapeutics Ltd. was founded in 2004 and is headquartered in Cambridge, Massachusetts.

Ad Paradigm Press

Forget Bitcoin. Crypto Millionaire Predicts 8,788% Gains For THIS

Click here to find out that this 8,788% cryptocurrency is.

ANCN Stock News Headlines

May 29, 2023 | finance.yahoo.com

Rakovina Therapeutics Inc. Announces 2022 Financial Results and Convertible Debenture Financing

May 27, 2023 | morningstar.com

ITeos Therapeutics Inc Ordinary Shares

April 20, 2024 | American Alternative (Ad)

Your Money is Not Safe

Biden Deploys Phase 1 Fednow Digital Currency Discover how to legally "opt-out" of the digital dollar today. No matter what they say, it's not something that will help you. If you don't take the action steps shown below…

May 20, 2023 | seekingalpha.com

ENDV Endonovo Therapeutics, Inc.

May 18, 2023 | msn.com

Looking Into Oncternal Therapeutics's Return On Capital Employed

May 18, 2023 | msn.com

Anticompetitive Behavior At United Therapeutics, Regeneron, And The FTC

May 16, 2023 | msn.com

FTC sues to block Amgen’s acquisition of Horizon Therapeutics

May 16, 2023 | msn.com

FTC sues to block Amgen acquisition of Horizon Therapeutics

April 20, 2024 | American Alternative (Ad)

Your Money is Not Safe

May 12, 2023 | msn.com

Recap: Abeona Therapeutics Q1 Earnings

May 9, 2023 | msn.com

TScan Therapeutics More than Doubles Following Deal with Amgen

April 26, 2023 | benzinga.com

Mersana Therapeutics Announces Upcoming Presentations at 2023 ASCO Annual Meeting

April 5, 2023 | finanznachrichten.de

Perspective Therapeutics, Inc.: Perspective Therapeutics Expands Management Team And Names Andrew Bright as Executive Vice-President of Brachytherapy

March 27, 2023 | news.yahoo.com

Cigna's PBM, two others sued in Ohio over drug price fixing - WSJ

February 25, 2023 | finanznachrichten.de

Defence Therapeutics Inc.: Defence Therapeutics and CQDM Fund the Development of a New Cancer Vaccine Platform

February 18, 2023 | benzinga.com

Voyager Therapeutics Stock (NASDAQ:VYGR), Quotes and News Summary

February 11, 2023 | yahoo.com

Molina Healthcare, Inc. (NYSE:MOH) Q4 2022 Earnings Call Transcript

February 10, 2023 | benzinga.com

Revance Therapeutics Stock (NASDAQ:RVNC), Quotes and News Summary

January 5, 2023 | markets.businessinsider.com

Jnana Therapeutics to Present at the 41st Annual J.P. Morgan Healthcare Conference

December 29, 2022 | msn.com

Down -41.38% in 4 Weeks, Here's Why Allogene Therapeutics (ALLO) Looks Ripe for a Turnaround

December 27, 2022 | benzinga.com

Onconova Therapeutics's Return On Capital Employed Insights

December 13, 2022 | barrons.com

3 Reasons Amgen Is Buying Horizon — and Why It Wasn’t the Only Company Interested

December 13, 2022 | msn.com

Amgen to buy Horizon Therapeutics in $26.4 billion deal

December 12, 2022 | msn.com

Here's Where Amgen's Loan To Acquire Horizon Therapeutics For $28B Ranks Among M&A Deals In 2022

December 12, 2022 | markets.businessinsider.com

Rule 2.7 Announcement: Amgen Inc to Acquire Horizon Therapeutics plc

December 12, 2022 | msn.com

Amgen secures $28.3 billion deal to buy Horizon Therapeutics

December 12, 2022 | msn.com

Amgen to Buy Horizon Therapeutics in $27.8 Billion Deal

See More Headlines

Receive ANCN Stock News and Ratings via Email

Sign-up to receive the latest news and ratings for Anchiano Therapeutics and its competitors with MarketBeat's FREE daily newsletter.

Company Calendar

Last Earnings: 8/05/2019
Today: 4/19/2024

Get Stock Alerts

Industry, Sector and Symbol

Stock Exchange: NASDAQ
Sector: Medical
Industry: Pharmaceutical Preparations
Sub-Industry: N/A
Current Symbol: NASDAQ:ANCN
CUSIP: N/A
CIK: N/A
Web: www.anchiano.com
Phone: 857-259-4622
Fax: N/A
Employees: 16
Year Founded: N/A

Profitability

EPS (Most Recent Fiscal Year): ($3.46)
Trailing P/E Ratio: 4.53
Forward P/E Ratio: N/A
P/E Growth: N/A
Net Income: $-27,120,000.00
Net Margins: N/A
Pretax Margin: N/A
Return on Equity: 36.08%
Return on Assets: 27.40%

Debt

Debt-to-Equity Ratio: N/A
Current Ratio: 3.25
Quick Ratio: 3.25

Sales & Book Value

Annual Sales: N/A
Price / Sales: N/A
Cash Flow: N/A
Price / Cash Flow: N/A
Book Value: $2.01 per share
Price / Book: 0.34

Miscellaneous

Outstanding Shares: 7,420,000
Free Float: N/A
Market Cap: $5.05 million
Optionable: Not Optionable
Beta: 0.93

13 Stocks Institutional Investors Won't Stop Buying

Which stocks are major institutional investors including hedge funds and endowments buying in today's market? Click the link below and we'll send you MarketBeat's list of thirteen stocks that institutional investors are buying up as quickly as they can.

Get This Free Report

Key Executives

Mr. Ronald K. Knickerbocker (Age 55)
Sr. VP of Clinical Devel. & Data Sciences
Comp: $352k
Mr. Neil H. Cohen (Age 58)
CEO & Director
Prof. Abraham Hochberg (Age 83)
Co-Founder & Chief Scientific Officer
Mr. Andrew Fine (Age 51)
Chief Financial Officer
Mr. Avraham Hampel M.B.A.
Deputy CFO & Company Sec.
Mr. Or Dolev (Age 43)
Controller

Key Competitors

View All Competitors

ANCN Stock Analysis - Frequently Asked Questions

How were Anchiano Therapeutics' earnings last quarter?: Anchiano Therapeutics Ltd. (NASDAQ:ANCN) posted its quarterly earnings results on Monday, August, 5th. The company reported ($0.05) earnings per share (EPS) for the quarter, beating the consensus estimate of ($0.17) by $0.12.
What other stocks do shareholders of Anchiano Therapeutics own?: Based on aggregate information from My MarketBeat watchlists, some companies that other Anchiano Therapeutics investors own include AbbVie (ABBV), Allena Pharmaceuticals (ALNA), Aileron Therapeutics (ALRN), Abeona Therapeutics (ABEO), Achieve Life Sciences (ACHV), Acorda Therapeutics (ACOR), Acasti Pharma (ACST), Aduro Biotech (ADRO) and AnaptysBio (ANAB).
When did Anchiano Therapeutics IPO?: Anchiano Therapeutics (ANCN) raised $35 million in an initial public offering (IPO) on Tuesday, February 12th 2019. The company issued 2,400,000 shares at $14.55 per share. Oppenheimer acted as the underwriter for the IPO and Ladenburg Thalmann was co-manager.

This page (NASDAQ:ANCN) was last updated on 4/20/2024 by MarketBeat.com Staff

From Our Partners

Get 30 Days of MarketBeat All Access Free

Best-in-Class Portfolio Monitoring
View the latest news, buy/sell ratings, SEC filings and insider transactions for your stocks. Compare your portfolio performance to leading indices and get personalized stock ideas based on your portfolio.
Stock Ideas and Recommendations
Get daily stock ideas from top-performing Wall Street analysts. Get short term trading ideas from the MarketBeat Idea Engine. View which stocks are hot on social media with MarketBeat's trending stocks report.
Advanced Stock Screeners and Research Tools
Identify stocks that meet your criteria using seven unique stock screeners. See what's happening in the market right now with MarketBeat's real-time news feed. Export data to Excel for your own analysis.

Start Your 30-Day Free Trial

Anchiano Therapeutics (ANCN) Stock Price, News & Analysis

About Anchiano Therapeutics Stock (NASDAQ:ANCN)

ANCN Stock News Headlines

Company Calendar

Industry, Sector and Symbol

Profitability

Debt

Sales & Book Value

Miscellaneous

Key Executives

Key Competitors

ANCN Stock Analysis - Frequently Asked Questions

About MarketBeat

MarketBeat Products

Popular Tools

Financial Calendars

Terms & Info